{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117219","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.309208+00:00","generated_at":"2026-06-08T04:58:51.715725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rezolute Q1 FY2024 net loss $14.5M; RZ358 Phase 3 start planned before year-end","bullets":["Net loss of $14.5M for Q1 FY2024 vs $9.8M in same period last year.","R&D expenses $12.2M (up 58% YoY) due to increased clinical and manufacturing costs.","Cash and investments $106.9M as of Sep 30, 2023, down from $118.4M at Jun 30, 2023.","RZ358 granted EMA PRIME designation; Phase 3 sunRIZE study for congenital hyperinsulinism to initiate Q4 2023.","RZ402 Phase 2 enrollment in diabetic macular edema near completion; update expected before year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117219","json":"https://secwatch.observer/filing/0001104659-23-117219.json","markdown":"https://secwatch.observer/filing/0001104659-23-117219.md","text":"https://secwatch.observer/filing/0001104659-23-117219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/0001104659-23-117219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/tm2330300d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:58:51.715725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}